Skip to main content
Premium Trial:

Request an Annual Quote

MetaStat Inks Deal to Access Kaiser Foundation Tumor Samples, Clinical Data

NEW YORK (GenomeWeb) - MetaStat today announced an agreement with the Kaiser Foundation to access tumor samples and clinical data from Kaiser Permanente hospitals.

Under the terms of the agreement, MetaStat will receive de-identified tissue samples, clinical data, and medical histories for up to 500 patients with or without metastatic breast cancer. The firm will test these samples with its MetaSite Breast and MenaCalc Breast diagnostic assays, which aim to predict systemic metastasis.

"These tissues samples will allow us to independently verify and validate results from the recently published study on the prediction of distant metastasis of breast cancer,” MetaStat CEO Oscar Bronsther said in a statement, referring to a study by Thomas Rohan and colleagues and published in the Journal of the National Cancer Institute

Boston-based MetaStat's diagnostic platform technology is built on identifying and understanding the role of the mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors.

The platform improves treatment planning decisions by stratifying patients based on the risk of metastasis, the firm said in a statement.

Financial details of the agreement were not disclosed.